At baseline, 6 (14.3%), 9 (21.4%), and 8 (25.0%) patients with BTC, ESCC, and HNSCC, respectively, had PD‐L1 expression of TC ≥ 25% (Table 1). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.